Skip to main content
NewslettersWatchlist

Nektar Therapeutics(NKTR-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low1.3700
Day High1.4200
Open:1.3700
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
PR Newswire
Nektar Presents New Responder Data for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy, in Late-Breaking News Oral Presentation at 2023 EADV Congress
PR Newswire
Nektar Therapeutics Announces Two Abstracts Accepted at EADV Congress 2023 for Rezpegaldesleukin, a First-in-Class Selective Regulatory T-cell Therapy
PR Newswire
Nektar Therapeutics to Host Virtual Investor & Analyst Event with Dermatology Experts on September 13th
PR Newswire
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
PR Newswire
Nektar Announces Promising New and Corrected Rezpegaldesleukin Efficacy Data Which Were Previously Reported in 2022 and Incorrectly Calculated by Former Collaborator Eli Lilly & Company
PR Newswire
Nektar to Announce Financial Results for the Second Quarter 2023 on Tuesday, August 8, 2023, After Close of U.S.-Based Financial Markets
PR Newswire
Nektar Therapeutics to Participate in Fireside Chat at the Goldman Sachs 44th Annual Global Healthcare Conference
PR Newswire
Nektar Therapeutics Reports First Quarter 2023 Financial Results
PR Newswire
Nektar Therapeutics Announces It Will Regain Full Rights to Rezpegaldesleukin (REZPEG, NKTR-358), a Novel, First-in-Class Selective Regulatory T-cell (Treg) Therapy in Clinical Development
PR Newswire
Nektar Therapeutics Announces Strategic Reprioritization and Cost Restructuring Plan
PR Newswire
Crane Set to Join S&P MidCap 400; PacWest Bancorp to Join S&P SmallCap 600
PR Newswire
Nektar Therapeutics Issues Statement Confirming That It Does Not Hold Any Cash Deposits or Securities at Silicon Valley Bank
PR Newswire
Nektar Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results
Barchart
Futures are Signaling a Weak Open for Wall Street, U.S. PCE Data In Focus
PR Newswire
Nektar Therapeutics Announces Phase 2 Topline Data for Rezpegaldesleukin in Patients with Systemic Lupus Erythematosus
Business Wire
Glancy Prongay & Murray LLP Announces Investigation of Nektar Therapeutics (NKTR)
PR Newswire
Nektar Therapeutics' President and CEO, Howard Robin, To Present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA
PR Newswire
Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm
PR Newswire
Nektar Announces Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting
PR Newswire
Nektar Therapeutics Presents Preclinical Data from Novel PEGylated Interferon Gamma Program, NKTR-288, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
PR Newswire
Nektar Therapeutics Reports Third Quarter 2022 Financial Results
PR Newswire
Nektar to Announce Financial Results for the Third Quarter 2022 on Thursday, November 3, 2022, After Close of U.S.-Based Financial Markets
PR Newswire
Moore Kuehn, PLLC Encourages Investors of Nektar Therapeutics to Contact Law Firm
PR Newswire
Nektar Therapeutics Presents Data for Rezpegaldesleukin (LY3471851) in Patients with Atopic Dermatitis and Psoriasis from Two Separate Clinical Studies at 2022 European Academy of Dermatology (EADV) Congress
PR Newswire
Nektar and Collaborators Announce Preclinical Publication of Data for NKTR-255 and its Observed Improvement of NK Cell Function in Multiple Myeloma
PR Newswire
Nektar Therapeutics Reports Second Quarter 2022 Financial Results
PR Newswire
Nektar to Announce Financial Results for the Second Quarter 2022 on Thursday, August 4, 2022, After Close of U.S.-Based Financial Markets
PR Newswire
Nektar Announces Promotion of Jillian B. Thomsen to Senior Vice President & Chief Financial Officer
Business Wire
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
Motley Fool
Why Nektar Therapeutics Stock Is Crashing Today
InvestorPlace
Knightscope News: Why Is KSCP Stock Up Today?
InvestorPlace
Why is Nektar Therapeutics (NKTR) Stock Down Today?

Profile

Nektar Therapeutics is a biopharmaceutical company, focused on the development of treatments utilizing its PEGylation and advanced polymer conjugate technology platforms. Nektar primarily finances its operations with funds from licensing, collaboration and manufacturing agreements. It has collaboration deals with companies namely AstraZeneca, Pfizer, Roche, Amgen, Bristol-Myers and Eli Lilly among others. The company's most lucrative deal is with Bristol-Myers, which provided the company with significant cash resources to support progress of its pipeline and share development costs for its lead candidate, bempegaldesleukin. Nektar recognizes product sales from its manufacturing and supply agreements with several pharma companies related to products developed using its PEGylation platform. The company also earns royalty payments from the sales of products using its technology platforms. Amgen's neutropenia drug, Neulasta is one of the drugs developed using Nektar's PEGylation platform.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.